# US 2025/0019379 A1 · New crystal form of compound, and preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0019379 A1
- Document ID: US20250019379A1
- Status: Published application
- Kind: A1
- Application number: 18/713,607
- Filed: 2022-11-22
- Published: 2025-01-16
- Earliest claimed: 2021-11-25
- Assignees: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
- Applicants: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
- Inventors: Pengfei LIU; Wang SHEN; Hongjun GAO; Shizhe DING
- Web page: https://patentgrep.com/patent/US20250019379A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 37/02: Immunomodulators
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a crystal form of a compound of formula (I), a method for preparing the crystal form, a pharmaceutical composition containing the crystal form, and the use thereof in the preparation of a drug for treating diseases, disorders or symptoms, or a method thereof for treating diseases, disorders or symptoms.

## Claims

### Claim 1

A crystalline form A of the compound of formula (I),
wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2θ angles of 8.6°±0.2°, 9.8°±0.2°, 10.7°±0.2°, 11.2°±0.2°, 12.3°±0.2°, 12.9°±0.2°, 16.0°±0.2°, and 19.0°±0.2°.

### Claim 2 (depends on 1)

The crystalline form A of claim 1, wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2θ angles of 8.6°±0.2°, 9.8°±0.2°, 10.7°±0.2°, 11.2°±0.2°, 12.3°±0.2°, 12.9°±0.2°, 16.0°±0.2°, 17.0°±0.2°, 17.4°±0.2°, 17.8°±0.2°, 19.0°±0.2°, 19.9°±0.2°, and 21.2°±0.2°.

### Claim 3 (depends on 1)

The crystalline form A of claim 1, wherein the X-ray powder diffraction pattern is substantially as shown in Table 1.

### Claim 4 (depends on 1)

The crystalline form A of claim 1, wherein the X-ray powder diffraction pattern is substantially as shown in FIG. 2.

### Claim 5

A crystalline form Q of the compound of formula (I),
wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2θ angles of 8.5°±0.2°, 14.5°±0.2°, 15.0°±0.2°, 16.8°±0.2°, 19.4°±0.2°, 23.6°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.4°±0.2°.

### Claim 6 (depends on 5)

The crystalline form Q of claim 5, wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2θ angles of 8.5°±0.2°, 14.5°±0.2°, 15.0°±0.2°, 15.8°±0.2°, 16.8°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 20.1°±0.2°, 23.6°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.4°±0.2°.

### Claim 7 (depends on 5)

The crystalline form Q of claim 5, wherein the X-ray powder diffraction pattern is substantially as shown in FIG. 13.

### Claim 8 (depends on 1)

A pharmaceutical composition, wherein the pharmaceutical composition comprises an effective therapeutic amount of the crystalline form A of claim 1, and pharmaceutically acceptable carriers, diluents or excipients.

### Claim 9 (depends on 5)

A pharmaceutical composition, wherein the pharmaceutical composition comprises an effective therapeutic amount of the crystalline form Q of claim 5, and pharmaceutically acceptable carriers, diluents or excipients.

### Claim 10 (depends on 1)

A method for preparing crystalline form A of claim 1, wherein the method comprises: dissolving the compound of formula (I) in ethanol until it is clear, and then concentrating; stirring the obtained concentrate, a solid precipitated; filtered and dried to obtain the crystalline form A.

### Claim at position 11

11-16. (canceled)

### Claim 17 (depends on 1)

A method for treating and/or preventing diseases, wherein the method comprises administering a therapeutically effective amount of the crystalline form of claim 1 to a mammal in need.

### Claim 18 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount is from 0.01 mg/kg body weight/day to 100 mg/kg body weight/day.

### Claim 19 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount is from 0.1 mg/kg body weight/day to 30 mg/kg body weight/day.

### Claim 20 (depends on 17)

The method of claim 17, wherein the disease is mediated by JAK kinase.

### Claim 21 (depends on 17)

The method of claim 17, wherein the mammal includes a companion animal.

### Claim 22 (depends on 17)

The method of claim 17, wherein the mammal includes a domestic animal.

### Claim 23 (depends on 17)

The method of claim 17, wherein the administering is performed orally, parenterally or topically.

### Claim 24 (depends on 8)

A method for treating and/or preventing diseases, wherein the method comprises administering a therapeutically effective amount of the pharmaceutical composition of claim 8 to a mammal in need.

### Claim 25 (depends on 24)

The method of claim 24, wherein the disease is mediated by JAK kinase.

### Claim 26 (depends on 9)

A method for treating and/or preventing diseases, wherein the method comprises administering a therapeutically effective amount of the pharmaceutical composition of claim 9 to a mammal in need.
